For human epidermal growth factor receptor 2 (HER2)-positive recurrent or metastatic cervical cancer, trastuzumab deruxtecan is now the treatment of choice, while larotrectinib is advised for patients with neurotrophic tyrosine receptor kinase (NTRK) fusion gene-positive tumors (39, 40). The gene discussed is ERBB2; the disease is cervical carcinoma.